Key result
Coenzyme Q10 shows potential as adjunctive therapy across multiple cardiovascular diseases.
Why the study?
This review summarizes 30 years of research on the potential of coenzyme Q10 for the prevention and treatment of cardiovascular disease.
CoQ10 may warrant study in statin-treated patients; leaves open large RCTs before any practice change.
This article provides a comprehensive review of 30 years of research on the use of coenzyme Q10 in prevention and treatment of cardiovascular disease. This endogenous antioxidant has potential for use in prevention and treatment of cardiovascular disease, particularly hypertension, hyperlipidemia, coronary artery disease, and heart failure. It appears that levels of coenzyme Q10 are decreased during therapy with HMG-CoA reductase inhibitors, gemfibrozil, Adriamycin, and certain beta blockers. Further clinical trials are warranted, but because of its low toxicity it may be appropriate to recommend coenzyme Q10 to select patients as an adjunct to conventional treatment.
No takes yet. Share an insight, caveat, or question.
Barbara Sarter (2002) conducted a review in Cardiovascular disease (including hypertension, hyperlipidemia, coronary artery disease, and heart failure). Coenzyme Q10 was evaluated. Coenzyme Q10 shows potential across 30 years of research as an adjunct for preventing and treating cardiovascular diseases including hypertension, hyperlipidemia, CAD, and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: